文献速递临床试验与 GCP基础与转化研究

铁蛋白纳米颗粒H2流感疫苗在健康成人中的安全性与免疫原性:一项1期试验

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
PubMed 文献 · Nat Med · 2022-02-03

开展首个人体、随机、开放标签1期临床试验,评估铁蛋白纳米颗粒H2HA疫苗平台。50名18-70岁健康成人接受单剂20μg或60μg两次同源或一次异源加强方案。两种疫苗安全且耐受良好,最常见局部症状为轻度头痛;在H2未暴露和暴露人群中均诱导中和抗体,H2未暴露人群还诱导针对1组流感病毒(含季节性H1和禽H5)的广谱中和抗体。

要点

  • 铁蛋白纳米颗粒H2HA疫苗单用或与H2 DNA疫苗序贯加强均安全耐受良好。
  • 最常见征集性症状为轻度头痛,H2HA-Ferritin组n=15(22%),H2 DNA组n=5(25%)。
  • H2未暴露和暴露成人均诱导中和抗体,H2未暴露者还产生针对HA茎部的1组流感广谱中和抗体。

核心结论

  • 铁蛋白纳米颗粒疫苗技术代表一种新型、安全且具有免疫原性的平台,可能应用于大流行准备和通用流感疫苗开发。

研究设计与样本

  • 首个人体、随机、开放标签1期临床试验(NCT03186781),评估铁蛋白(H2HA-Ferritin)纳米颗粒流感疫苗平台。
  • 50名18-70岁健康参与者肌肉注射H2HA-Ferritin:单剂20μg(n=5)或60μg两次同源初免-加强(n=25)或经匹配H2 DNA疫苗初免后一次异源初免-加强(n=20)。
  • 主要目标为评估H2HA-Ferritin单用或初免-加强方案的安全性和耐受性;次要目标为评估接种后抗体应答。

主要发现

  • 两种疫苗均安全且耐受良好,最常见征集性症状为轻度头痛,H2HA-Ferritin组n=15(22%),H2 DNA组n=5(25%)。
  • 探索性分析发现H2HA-Ferritin疫苗在H2未暴露和H2暴露人群中均诱导中和抗体应答。
  • H2未暴露人群通过靶向HA茎部诱导针对1组流感病毒(包括季节性H1和禽H5亚型)的广谱中和抗体应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, licensed seasonal influenza vaccines display variable vaccine effectiveness, and there remains a need for novel vaccine platforms capable of inducing broader responses against viral protein domains conserved among influenza subtypes. We conducted a first-in-human, randomized, open-label, phase 1 clinical trial ( NCT03186781 ) to evaluate a novel ferritin (H2HA-Ferritin) nanoparticle influenza vaccine platform. The H2 subtype has not circulated in humans since 1968. Adults born after 1968 have been exposed to only the H1 subtype of group 1 influenza viruses, which shares a conserved stem with H2. Including both H2-naive and H2-exposed adults in the trial allowed us to evaluate memory responses against the conserved stem domain in the presence or absence of pre-existing responses against the immunodominant HA head domain. Fifty healthy participants 18-70 years of age received H2HA-Ferritin intramuscularly as a single 20-μg dose (n = 5) or a 60-μg dose either twice in a homologous (n = 25) prime-boost regimen or once in a heterologous (n = 20) prime-boost regimen after a matched H2 DNA vaccine prime. The primary objective of this trial was to evaluate the safety and tolerability of H2HA-Ferritin either alone or in prime-boost regimens. The secondary objective was to evaluate antibody responses after vaccination. Both vaccines were safe and well tolerated, with the most common solicited symptom being mild headache after both H2HA-Ferritin (n = 15, 22%) and H2 DNA (n = 5, 25%). Exploratory analyses identified neutralizing antibody responses elicited by the H2HA-Ferritin vaccine in both H2-naive and H2-exposed populations. Furthermore, broadly neutralizing antibody responses against group 1 influenza viruses, including both seasonal H1 and avian H5 subtypes, were induced in the H2-naive population through targeting the HA stem. This ferritin nanoparticle vaccine technology represents a novel, safe and immunogenic platform with potential application for pandemic preparedness and universal influenza vaccine development.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Houser KV, Chen GL, Carter C, et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat Med. 2022. PMID: 35115706. doi:10.1038/s41591-021-01660-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。